Posts by: Joana Carvalho

Joana Carvalho

Joana holds a BSc in Biology, a MSc in Evolutionary and Developmental Biology and a PhD in Biomedical Sciences from Universidade de Lisboa, Portugal. Her work has been focused on the impact of non-canonical Wnt signaling in the collective behavior of endothelial cells — cells that made up the lining of blood vessels — found in the umbilical cord of newborns.

March 5, 2021March 5, 2021

Dry Powder Inhalers OK Despite Less Respiratory Muscle Strength

News

Despite having lower respiratory muscle strength, people with pulmonary arterial hypertension (PAH) can still use dry powder inhalers that require breath-actuated force to effectively deliver inhaled therapies, a study has ... Read more

February 24, 2021February 24, 2021

Insmed Announces Top-line Results from Phase 1 Trial of TPIP

News, PAH News

Top-line data from a Phase 1 clinical trial has found that treprostinil palmitil inhalation powder (TPIP) — a dry powder form of a treprostinil precursor that is being developed by ... Read more

February 22, 2021February 22, 2021

FDA Approves Alembic’s Generic Injection of Remodulin for PAH

News, PAH News

The U.S. Food and Drug Administration (FDA) has approved Alembic Pharmaceuticals’ injectable formulation of treprostinil, a generic version of Remodulin, to treat patients with pulmonary arterial hypertension (PAH), the company ... Read more

January 6, 2021January 6, 2021

FDA Priority Review Likely for Tyvaso DPI, Inhaled Treprostinil for PAH

News

United Therapeutics is planning to ask the U.S. Food and Drug Administration (FDA) for an accelerated review of Tyvaso DPI, an investigational therapy-inhaler device treatment for two forms of pulmonary hypertension, in ... Read more

December 2, 2020December 2, 2020

UK Adults With PH Urged to Assess Self-help Program for Anxiety

News, PH News

The Pulmonary Hypertension Association U.K. (PHA UK), a charity organization dedicated to supporting those with pulmonary hypertension (PH), is urging adults with PH to participate in a research study assessing ... Read more

November 30, 2020November 30, 2020

FDA Requests More Data to Support LIQ861’s Potential Approval for PAH

News, PAH News

The U.S. Food and Drug Administration (FDA) determined that additional data is required to support the potential approval of LIQ861, Liquidia Technologies’ investigational inhaled formulation of treprostinil, for the treatment ... Read more

November 25, 2020November 30, 2020

Liquidia Completes RareGen Acquisition, Strengthening Commitment to PAH

News, PAH News

Liquidia Technologies, the developer of an inhaled formulation of treprostinil (LIQ861) for the treatment of pulmonary arterial hypertension (PAH), has completed its acquisition of RareGen, the marketer of generic treprostinil ... Read more

October 19, 2020October 19, 2020

Tenax Acquires Rights to Oral Levosimendan, Plans Phase 3 Trial in Type 2 PH

News, PH News

Tenax Therapeutics has acquired developmental and commercial rights for North America to an oral formulation of levosimendan, a potential therapy for pulmonary hypertension and heart failure with preserved ejection fraction ... Read more

October 5, 2020October 5, 2020

Imbalance in Gut Bacteria Composition May Play Key Role in PAH

News

An imbalance in the composition of bacteria living in the gut, a phenomenon known as dysbiosis, may play a key role in the onset and progression of pulmonary arterial hypertension ... Read more

September 21, 2020September 21, 2020

Moderna, Chiesi Will Collaborate on New RNA-based Therapies for PAH

News, PAH News

Moderna has entered a collaboration agreement with Chiesi Farmaceutici to develop new messenger RNA-based therapies for pulmonary arterial hypertension (PAH). Messenger RNAs (mRNAs) are the molecules that cells use as ... Read more